Detalhe da pesquisa
1.
Novel FtsZ inhibitor with potent activity against Staphylococcus aureus.
J Antimicrob Chemother
; 76(11): 2867-2874, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34383913
2.
DS86760016, a Leucyl-tRNA Synthetase Inhibitor with Activity against Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 63(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30670430
3.
In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437618
4.
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother
; 62(6)2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29610202
5.
In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439962
6.
Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.
Antimicrob Agents Chemother
; 62(5)2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29439973
7.
Effect of DS-2969b, a novel GyrB inhibitor, on rat and monkey intestinal microbiota.
Anaerobe
; 51: 120-123, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29758524
8.
Azithromycin Exhibits Activity Against Pseudomonas aeruginosa in Chronic Rat Lung Infection Model.
Front Microbiol
; 12: 603151, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33967970
9.
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 53(3): 1238-41, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19104025
10.
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 52(8): 2849-54, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519723
11.
A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor.
J Clin Pharmacol
; 58(12): 1557-1565, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29746725
12.
Identification of the biosynthetic gene cluster of A-500359s in Streptomyces griseus SANK60196.
J Antibiot (Tokyo)
; 62(6): 325-32, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19478828
13.
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Antimicrob Agents Chemother
; 49(8): 3239-50, 2005 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16048932
14.
Regulatory network of acid resistance genes in Escherichia coli.
Mol Microbiol
; 48(3): 699-712, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12694615
15.
Escherichia coli gene expression responsive to levels of the response regulator EvgA.
J Bacteriol
; 184(22): 6225-34, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12399493
16.
Characterization of EvgAS-YdeO-GadE branched regulatory circuit governing glutamate-dependent acid resistance in Escherichia coli.
J Bacteriol
; 186(21): 7378-89, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15489450
17.
A motif co-occurrence approach for genome-wide prediction of transcription-factor-binding sites in Escherichia coli.
Genome Res
; 14(2): 201-8, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14762058